培门冬酶与左旋门冬酰胺酶治疗Ph阴性急性淋巴细胞白血病的对比研究

Comparison of efficacy and security between pegaspargase and L-asparaginase in treatment of Ph-negative acute lymphoblastic leukemia

目的比较培门冬酶与左旋门冬酰胺酶治疗Ph阴性急性淋巴细胞白血病的效果及安全性。方法回顾性分析连云港市第一人民医院2007年1月~2018年3月收治的52例Ph阴性急性淋巴白血病患者的临床资料,患者均接受VDCLP方案化疗,按照用药分为培门冬酶组(25例)与左旋门冬酰胺酶组(27例),比较两组的疗效、不良反应及生存情况。结果培门冬酶组及左旋门冬酰胺酶组患者的一般资料比较,差异无统计学意义(P>0.05)。两组总有效率比较,差异无统计学意义(P>0.05)。左旋门冬酰胺酶组的过敏发生率及高血糖发生率高于培门冬酶组(P<0.05),培门冬酶组的纤维蛋白原(FIB)最低值较左旋门冬酰胺酶组高,活化部分凝血活酶时间(APTT)持续增高时间较左旋门冬酶胺组短(P<0.05)。结论培门冬酶治疗Ph阴性急性淋巴细胞白血病效果好、安全,值得临床推广。

Objective To compare the efficacy and security between pegaspargase and L-asparaginase in the treatment of Ph-negative acute lymphoblastie leukemia. Methods Clinical data of 52 Ph-negative acute lymphoblastie leukemia cases admitted to the First People＇s Hospital of Lianyungang from January 2007 to March 2018 were retrospectively analyzed. All the cases received VDCLP chemotherapy and were divided into the pegaspargase group （25 cases） and the L-asparaginase group （27 cases）. The efficacy, adverse reactions and survival status between the two groups were compared. Results The general information between the two groups were homogeneous, there was no statistically significant difference （P 〉 0.05）. There was no statistically significant difference in the total effective rate between the two groups （P 〉 0.05）. The incidence of allergic reactions and hyperglycemia in the L-aspar%oinase group was higher than that in the pegaspargase group （P 〈 0.05）. The minimum value of fibrinogen （FIB） in the pegaspargase group was bigger than the L-asparaginase group, and the duration rise time of activated partial thromboplastin time in the pegaspargase group was shorter than the L-asparaginase group （P 〈 0.05）. Conclusion Pegaspargase is effective and safe in the treatment of Ph-negative acute lymphoblastie leukemia and it is worth of clinical promotion.